Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevacizumab + rituximab + CHOP
- Development stage
- Discontinued
- Lead developer
- Genentech
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
Bevacizumab + rituximab + CHOP is a combination therapy regimen that merges the anti-VEGF monoclonal antibody bevacizumab, the anti-CD20 monoclonal antibody rituximab, and the CHOP chemotherapy protocol (cyclophosphamide, doxorubicin, vincristine, and prednisone/prednisolone). Bevacizumab targets vascular endothelial growth factor A (VEGF-A), inhibiting tumor angiogenesis. Rituximab targets CD20 on B cells, promoting immune-mediated cell lysis. CHOP is a widely used cytotoxic chemotherapy regimen for non-Hodgkin lymphoma. This combination has been investigated as initial therapy for diffuse large B-cell lymphoma (DLBCL) and other aggressive B-cell lymphomas, but was discontinued in later-stage trials due to increased cardiotoxicity and lack of efficacy improvement over standard regimens[1][3][4][5][7].
- Other names
- bevacizumab + R-CHOPbevacizumab + rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone
02
Targets
CD20 (B-lymphocyte antigen CD20)TOP2A (DNA topoisomerase II)TUBB (Tubulin (alpha and beta subunits))VEGFA (Vascular endothelial growth factor A)GR (Glucocorticoid receptor)DNA
Beyond the preview
Go deeper on bevacizumab + rituximab + CHOP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevacizumab + rituximab + CHOP.